Comparison of mRNA splicing assay protocols across multiple laboratories: Recommendations for best practice in standardized clinical testing

Clinical Chemistry

Volumn 60, Issue 2, 2014, Pages 341-352

  Whiley, Phillip J ^a,b   De La Hoya, Miguel ^c   Thomassen, Mads ^d   Becker, Alexandra ^e,f   Brandão, Rita ^g   Pedersen, Inge Sokilde ^h   Montagna, Marco ⁱ   Menéndez, Mireia ^j   Quiles, Francisco ^j   Gutiérrez Enríquez, Sara ^k   Leeneer, Kim De ^l   Tenés, Anna ^k   Montalban, Gemma ^k   Tserpelis, Demis ^g   Yoshimatsu, Toshio ^m   Tirapo, Carole ⁿ   Raponi, Michela ^o   Caldes, Trinidad ^c   Blanco, Ana ^o   Santamariña, Marta ^p   Guidugli, Lucia ^q   De Garibay, Gorka Ruiz ^c   Wong, Ming ^r   Tancredi, Mariella ^s   Fachal, Laura ^o   Ding, Yuan Chun ^t   Kruse, Torben ^d   Lattimore, Vanessa ^u   Kwong, Ava ^v   Chan, Tsun Leung ^v   Colombo, Mara ^w   De Vecchi, Giovanni ^w   Caligo, Maria ^r   Baralle, Diana ^o   Lázaro, Conxi ^j   Couch, Fergus ^p   Radice, Paolo ^w   Southey, Melissa C ^q   Neuhausen, Susan ^t   Houdayer, Claude ⁿ   Fackenthal, Jim ^m   Van Overeem Hansen, Thomas ^x   Vega, Ana ^o   Diez, Orland ^k   Blok, Rien ^g   Claes, Kathleen ^l   Wappenschmidt, Barbara ^e,f   Walker, Logan ^u   Spurdle, Amanda B ^a   Brown, Melissa A ^b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^l UNIVERSITY OF CHICAGO   (United States)

^m INSTITUT CURIE   (France)

ⁿ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^o UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^p Mayo Clinic   (United States)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r UNIVERSITY OF PISA   (Italy)

^s CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^t NATIONAL CANCER INSTITUTE   (Italy)

^u Rigshospitalet   (Denmark)

^v UNIVERSITY OF OTAGO   (New Zealand)

^w GHENT UNIVERSITY HOSPITAL   (Belgium)

^x HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ACCURACY; AGAR GEL ELECTROPHORESIS; ARTICLE; ASSAY; BREAST CANCER; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; EXON SKIPPING; GENETIC VARIABILITY; HUMAN; LABORATORY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RNA SPLICING;

BRCA1 PROTEIN; BRCA2 PROTEIN; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LABORATORIES; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; RNA SPLICE SITES; RNA SPLICING; SENSITIVITY AND SPECIFICITY;

EID: 84893496863     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.210658     Document Type: Article

References (29)

1. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83.
2. Chatterjee S, Pal JK. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 2009;101:251-62
3. Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, et al. Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat 2012;33:1665-75.
4. Chen X, Truong T-TN, Weaver J, Bove BA, Cattie K, Armstrong BA, et al. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 2006;27:427-35.
5. Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, et al. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 2006;43:74-83.
6. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008;68:3523-31.
7. Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutierrez-Enriquez S, et al. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat 2012;132:1009-23.
8. Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, et al. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 2010;31:E1484-505.
9. Vreeswijk MP, Kraan JN, Van Der Klift HM, Vink GR, Cornelisse CJ, Wijnen JT, et al. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 2009;30:107-14.
10. Mucaki EJ, Ainsworth P, Rogan PK. Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants. Hum Mutat 2011;32:735-42.
11. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2variants. Hum Mutat 2012;33:1228-38.
12. Houdayer C, Dehainault C, Mattler C, Michaux D, Caux-Moncoutier V, Pages-Berhouet S, et al. Evaluation of in silico splice tools for decisionmaking in molecular diagnosis. Hum Mutat 2008;29:975-82.
13. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol 2011;22(Suppl 1):i18-23.
14. Sanz DJ, Acedo A, Infante M, Duran M, Perez-Cabornero L, Esteban-Cardenosa E, et al. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 2010;16:1957-67.
15. Walker LC, Whiley PJ, Houdayer C, Hansen TO, Vega A, Santamarina M, et al. Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. Hum Mutat 2013;34:1424-31.
16. Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A, Messiaen L. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2 Genes. Chrom Cancer 2003;37:314-20.
17. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotypephenotype correlation. Nat Genet 1995;11:428-33.
18. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008;8:140.
19. Menendez M, Castellsague J, Mirete M, Pros E, Feliubadalo L, Osorio A, et al. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2genes. Breast Cancer Res Treat 2012;132:979-92.
20. Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS, et al. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001;17:520-1.
21. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012;33:2-7.
22. Tesoriero AA, Wong EM, Jenkins MA, Hopper JL, Brown MA, Chenevix-Trench G, et al. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum Mutat 2005;26:495.
23. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, et al. Screening BRCA1 and BRCA2unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008;45:438-46.
24. Thery JC, Krieger S, Gaildrat P, Revillion F, Buisine MP, Killian A, et al. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 2011;19:1052-8.
25. Colombo M, De Vecchi G, Caleca L, Foglia C, Ripamonti CB, Ficarazzi F, et al. Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2genes and characterization of novel pathogenic mutations. PLoS One 2013;8:e57173.
26. Taberlet P, Griffin S, Goossens B, Questiau S, Manceau V, Escaravage N, et al. Reliable genotyping of samples with very low DNA quantities using PCR. Nucleic Acids Res 1996;24:3189-94.
27. Spurdle AB, Couch FJ, Hogervorst FB, Radice P, Sinilnikova OM. Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat 2008;29:1304-13.
28. Orban TI, Olah E. Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun 2001;280:32-8.
29. Sevcik J, Falk M, Macurek L, Kleiblova P, Lhota F, Hojny J, et al. Expression of human BRCA1 Delta17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response. Cell Signal 2013;25:1186-93.